PVR and neoplasm: By upregulating the expression of immunological checkpoint molecules such as PD-L1, CTLA-4, VISTA, Gal-9, and CD155, MDSCs impede tumor-infiltrating CD8+ T-cell-mediated anti-tumor immunity.